Cardiovascular panel relents

BETHESDA, Md. - The Cardiorenal Drugs Advisory Committee's 8-2 vote last week to recommend approval of SmithKline Beecham's Coreg (carvedilol) could be good news for Intercardia Inc., which is conducting Phase III trials of a similar drug, bucindelol. Coreg and bucindelol are third generation non-specific beta blockers, with vasodilating and antioxidant properties.

This is the second go-round for Coreg. Last May, the FDA panel (CDAC) recommended that the agency not approve Coreg. That decision significantly cut Coreg's lead over bucindolol. Intercardia (ITRC, Research Triangle Park, N.C.), which is majority owned by Interneuron Pharmaceuticals Inc. (IPIC, Lexington, Mass.), began Phase III

Read the full 990 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE